SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Cash Cat

Cash Cat is generating significant buzz following its listing on the Robinhood platform, with community members actively debating its potential as a leading meme coin on the new chain. While some investors view the asset as a high-conviction play ripe for accumulation, others are expressing caution regarding market volatility and the speculative nature of recent price action.

PENGU is the official coin of Pudgy Penguins.  Pudgy Penguins has become the face of crypto with one of the most influential communities in the industry. From large companies wearing the Penguin, to being featured in ETF commercials, to garnering millions of followers and over 100 billion views, the Pengu has become a cultural icon making PENGU the world’s social currency.  PENGU allows for the ever-expanding Pudgy Penguin fanbase and the hundreds of millions of people outside of crypto that see and share the Pudgy Penguin everyday, to join The Huddle. PENGU is a symbol for community, memes, and good vibes.  Believe in Pengu. Believe in the Prophecy.

Pudgy Penguins

Pudgy Penguins is trending as holders speculate on a breakout, with community sentiment divided between those betting on brand utility and long-term ecosystem growth and those frustrated by recent price volatility. While some see the current consolidation as an accumulation opportunity ahead of broader market shifts, others remain skeptical about the lack of immediate upward momentum.

Jersey Mike's Subs, Inc. engages in franchising fast casual, submarine-style sandwich restaurants specializing in authentic, hand-crafted, and craveable subs. The company was founded by Peter Cancro in 1956 and is headquartered in Tinton Falls, DE.

Jersey Mike`s Subs Inc. - Ordinary Shares - Class A

Jersey Mike's is currently a hot topic following its public market debut, with the community actively debating whether the brand's rapid growth and strong consumer loyalty can justify its valuation. While some investors view the stock as a long-term growth opportunity, many are cautious due to concerns about the impact of the IPO's lockup, the company's debt levels, and the general challenges facing the competitive quick-service restaurant sector.

USA Rare Earth, Inc. is a domestic supplier of rare earth magnets and heavy rare earth elements. It develops a vertically integrated domestic supply chain for rare earth element magnet production, with a facility in Stillwater and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth is trending as investors weigh aggressive government funding and legislative pushes to reshore critical mineral supply chains against volatility in the broader mining sector. Community discussion is heavily focused on the stock's role in counteracting Chinese dominance in magnet production, with traders debating whether ongoing acquisition efforts and strategic partnerships will provide the necessary momentum to break through current resistance levels.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Dallas, TX.

United States Antimony Corp.

United States Antimony Corp. is seeing a surge in community engagement driven by the CEO's upcoming appearance on national television and anticipation surrounding the company's critical role in domestic defense and munitions supply chains. Investors are actively debating the impact of government-backed strategic mineral initiatives while closely monitoring institutional buying trends despite recent volatility in the broader sector.

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the following segments: Materials and Magnetics. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

MP Materials Corporation

MP Materials is experiencing heavy volatility as investors weigh the company's critical role in U.S. defense supply chains and long-term domestic magnet manufacturing against ongoing market pressure from short selling and sector-wide weakness. Community discussion is currently focused on the company's strategic importance, anticipation of upcoming earnings, and the potential for a rebound driven by policy tailwinds and sustained demand for domestic rare-earth resources.

Norwegian Cruise Line Holdings Ltd. engages in the provision of cruise travel services. It offers cruise experiences for travelers with itineraries in Europe, Asia, Australia, New Zealand, South America, Africa, Canada, Bermuda, Caribbean, Alaska and Hawaii. Its brands include Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises. The company was founded in 1966 and is headquartered in Miami, FL.

Norwegian Cruise Line Holdings Ltd

Norwegian Cruise Line Holdings Ltd (NCLH) is facing heavy selling pressure as investors react to lowered full-year guidance and concerns over soft demand trends extending through 2027. While some in the community see the current dip as a potential entry point given the travel industry's recovery, many active traders are voicing intense frustration over persistent volatility, alleged market manipulation, and the stock's laggard performance relative to cruise peers.

REalloys, Inc. is engaged in the rebuilding of domestic supply chain resilience for rare earth elements and magnets. It is involved in recycling, mining, oxide production, metallization, alloying, and magnet manufacturing. The company was founded on October 4, 2011 and is headquartered in Boca Raton, FL.

REalloys Inc.

REalloys is attracting significant attention as investors react to its strategic partnership with the U.S. Army to develop domestic heavy rare earth processing, alongside recent institutional funding. The community is actively debating the stock's potential as a critical player in the effort to reshore U.S. supply chains ahead of 2027, with vocal discussions highlighting both bullish sentiment regarding government support and skepticism from those questioning the volatility and short-selling activity.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

Cipher Mining is drawing significant investor interest as community members discuss the company's shift toward high-performance computing and data center infrastructure. The conversation is currently focused on the company's ability to execute on project timelines and its potential role as a critical power-constrained play in the growing AI sector.

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. The company was founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 and is headquartered in New York, NY.

fuboTV Inc - Ordinary Shares - Class A

fuboTV Inc

FuboTV is currently attracting significant attention as investors speculate on the impact of new CEO Alisa Bowen, a former Disney+ executive, and the potential for closer integration within the Disney ecosystem. Community discussion is heavily divided between those betting on an undervalued turnaround fueled by the Disney partnership and skeptics concerned about the company's long-term viability, debt, and the recent sell-off activity by former management.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vanda Pharmaceuticals is trending as investors monitor the commercial launch of NEREUS for motion sickness and debate the company's potential as a buyout target for major pharmaceutical firms. The community is actively discussing the firm's strategic focus on GLP-1 adjunct treatments and pipeline developments while balancing optimism against frustrations over persistent price volatility.

Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Lags Revenue Estimates

Vanda (VNDA) delivered earnings and revenue surprises of -103.92% and -19.35%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results

Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results PR Newswire WASHINGTON, Aug. 5, 2026 Fanapt Q2 2026 net product sales increased 23% to $36.0 million; total prescriptions increased 31%Full-year 2026 total revenue...

Vanda Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 5, 2026

Vanda Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 5, 2026 Vanda Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 5, 2026 PR Newswire WASHINGTON, July 29, 2026 Conference Call and Webcast to FollowWASHINGTON, July 29, 2026 /PRNewswire...

Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis - A Milestone Recognition of GPP as a Distinct Rare Disease in Europe

Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis - A Milestone Recognition of GPP as a Distinct Rare Disease in Europe Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab...

NEREUS Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment

NEREUS Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment NEREUS Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment PR Newswire WASHINGTON, July 15, 2026 WASHINGTON, July...

Vanda Pharmaceuticals Announces Participation in the B. Riley Securities 2026 Mind, Muscle & Vision Summit

Vanda Pharmaceuticals Announces Participation in the B. Riley Securities 2026 Mind, Muscle & Vision Summit Vanda Pharmaceuticals Announces Participation in the B. Riley Securities 2026 Mind, Muscle & Vision Summit PR Newswire WASHINGTON, July 10, 2026 WASHINGTON, July 10, 2026 /PRNewswire/ -- Vanda...

VNDA Stock Gains After-Hours As FDA Grants Rare Pediatric Disease Designation For Experimental Therapy

Equity

The designation covers VCA-894A, Vanda’s investigational treatment for Charcot-Marie-Tooth disease type 2S. 


Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S

Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S PR Newswire...

Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis

Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis PR Newswire WASHINGTON, May 27, 2026 WASHINGTON, May 27, 2026...

Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences

Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences PR Newswire WASHINGTON, May 7, 2026...

$VNDA Q2 '26 Earnings Results & Recap

• Reported GAAP EPS of -$1.04 down -126.09% YoY
• Reported revenue of $1.03M down -98.04% YoY
• Vanda Pharmaceuticals Inc. is reiterating its 2026 total revenue guidance of $240 million to $290 million and expects to achieve various financial objectives across its product portfolio throughout the year.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$5.00
Prev Close	$5.12
Open	$5.16
Dividend Yield	0.00%
50-Day Moving Average	$5.80
Beta	0.80
Avg. Volume	830,936.28
PE Ratio	-1.08

52-Week High	$9.94
52-Week Low	$4.15
Market Capitalization	$302.31M
EPS (Annual)	-$3.74
Price to Book	1.37
Revenue Per Employee	$405,450.28

Feed

News

Sentiment

Earnings

Fundamentals

Info